MARKET

VIRI

VIRI

Virios Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.16
-0.18
-2.16%
After Hours: 8.00 -0.16 -1.96% 19:27 01/15 EST
OPEN
8.20
PREV CLOSE
8.34
HIGH
8.45
LOW
7.90
VOLUME
257.03K
TURNOVER
--
52 WEEK HIGH
16.71
52 WEEK LOW
7.16
MARKET CAP
63.91M
P/E (TTM)
-25.8391
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off
JPMorgan Chase & Co. CEO Jamie Dimon is to be among the keynote speakers at next week's J.P. Morgan Healthcare Conference.
Benzinga · 6d ago
Virios Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
Virios Therapeutics, Inc. (VIRI) will present at the H.C. Wainwright Virtual BioConnect Conference, taking place January 11-14, 2021.
Business Wire · 01/04 21:05
The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 29)
Benzinga · 12/30/2020 13:08
The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28)
Benzinga · 12/29/2020 13:09
The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 22)
Benzinga · 12/23/2020 13:29
The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 20)
Benzinga · 12/22/2020 12:45
Virios Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Over-Allotment Option
Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, today announced the closing of its initial public offering of 3,450,000 shares of its common stock at a public offering price of $10.00 per share, which includes 450,000 shares sold upon full exercise of the underwriter’s option to purchase additional common shares. The gross proceeds from the offering, including the exercise of the over-allotment option, were $34,500,000, before deducting underwriting discounts, commissions and offering expenses.
Business Wire · 12/21/2020 20:00
ONVO, UAVS, MESO and APDN among midday movers
Gainers: CURO Group (CURO) +78%.Mereo BioPharma (MREO) +49%.Cyclo Therapeutics (CYTH) +42%.China Green Agriculture (CGA) +30%.Origin Agritech (SEED) +23%.Upstart (UPST) +22%.AgEagle Aerial Systems (UAVS) +22%.Elys Game Technology (ELYS) +22%.Organovo (ONVO) +21%.Aqua Metals (AQMS)
Seekingalpha · 12/18/2020 17:39
More
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VIRI. Analyze the recent business situations of Virios Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About VIRI
Virios Therapeutics LLC is a development-stage biotechnology company focused on advancing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM). Its lead development candidate is IMC-1, which is a fixed dose combination of famciclovir and celecoxib. IMC-1 represents a combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1 (HSV-1) activation and replication. IMC-1 combines two specific mechanisms of action purposely designed to inhibit HSV-1 activation and replication, thereby keeping HSV-1 in a latent (dormant) state or down-regulating HSV-1 from a lytic (active) state back to latency. The famciclovir component of IMC-1 inhibits viral DNA replication and thus inhibits upregulation of the HSV-1 virus. The celecoxib component of IMC-1 inhibits cyclooxegenase-2 (COX-2) and to a lesser degree COX-1, enzymes used by HSV-1 to amplify or accelerate its own replication.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Virios Therapeutics LLC stock information, including NASDAQ:VIRI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIRI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VIRI stock methods without spending real money on the virtual paper trading platform.